Literature DB >> 14574036

Atrial fibrillation: the role of atrial defibrillation.

Massimo Santini1, Renato Ricci.   

Abstract

Dual defibrillator implantation represents an emerging option to treat patients with drug refractory atrial fibrillation. Atrial antitachycardia pacing and cardioversion have been demonstrated to be highly effective in treating spontaneous tachyarrhythmias and may reduce atrial fibrillation burden by preventing atrial remodeling. Device implantation has been associated to improved quality of life and reduced hospitalization rate. Patient selection and tailored device programming are critical as regard to clinical outcome. Individual psychological profile analysis as well as underlying heart disease and atrial fibrillation clinical patterns represent the main drivers for the right strategy. Controlled studies are needed in order to define the subset of patients who can benefit more from device implantation.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14574036     DOI： 10.1023/a:1026244726090

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN： 1383-875X            Impact factor:   1.900


  22 in total

Review 1.  The impact of the implantable cardioverter defibrillator on quality of life.

Authors:  R D Gallagher; S McKinley; B Mangan; D Pelletier; J Squire; S Mitten-Lewis
Journal:  Am J Crit Care       Date:  1997-01       Impact factor: 2.228

2.  Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and nontreated episodes. Metrix Investigators.

Authors:  C Timmermans; S Lévy; G M Ayers; W Jung; L Jordaens; M Rosenqvist; B Thibault; J Camm; L M Rodriguez; H J Wellens
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

3.  Single shock endocavitary low energy intracardiac cardioversion of chronic atrial fibrillation.

Authors:  M Santini; C Pandozi; G Altamura; G Gentilucci; M Villani; M C Scianaro; A Castro; F Ammirati; B Magris
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

4.  Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia.

Authors:  M E Hamer; J A Blumenthal; E A McCarthy; B G Phillips; E L Pritchett
Journal:  Am J Cardiol       Date:  1994-10-15       Impact factor: 2.778

5.  Atrial therapies reduce atrial arrhythmia burden in defibrillator patients.

Authors:  P A Friedman; B Dijkman; E N Warman; H A Xia; R Mehra; M S Stanton; S C Hammill
Journal:  Circulation       Date:  2001-08-28       Impact factor: 29.690

6.  Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator.

Authors:  S W Adler; C Wolpert; E N Warman; S K Musley; J L Koehler; D E Euler
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

7.  Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias.

Authors:  M R Gold; N Sulke; D S Schwartzman; R Mehra; D E Euler
Journal:  J Cardiovasc Electrophysiol       Date:  2001-11

8.  Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation.

Authors:  H F Tse; C P Lau; C M Yu; K L Lee; G F Michaud; B P Knight; F Morady; S A Strickberger
Journal:  J Cardiovasc Electrophysiol       Date:  1999-09

9.  Internal defibrillation: pain perception of low energy shocks.

Authors:  David M Steinhaus; Debbie S Cardinal; Luc Mongeon; Shailesh Kumar Musley; Laura Foley; Susie Corrigan
Journal:  Pacing Clin Electrophysiol       Date:  2002-07       Impact factor: 1.976

10.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.

Authors:  M C Wijffels; C J Kirchhof; R Dorland; M A Allessie
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.